| Autor: |
Nan Niu, Fang Qiu, Qianshi Xu, Guijin He, Xi Gu, Wenbin Guo, Dianlong Zhang, Zhigao Li, Yi Zhao, Yong Li, Ke Li, Hao Zhang, Peili Zhang, Yuanxi Huang, Gangling Zhang, Hongbin Han, Zhengang Cai, Pengfei Li, Hong Xu, Guanglei Chen, Jinqi Xue, Xiaofan Jiang, Alireza Hamidian Jahromi, Jinshi Li, Yu Zhao, Eduardo de Faria Castro Fleury, Shiwen Huo, Huajun Li, Guy Jerusalem, Domenico Tripodi, Tong Liu, Xinyu Zheng, Caigang Liu |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2041-1723 |
| DOI: |
10.1038/s41467-022-34838-w |
| Popis: |
Neoadjuvant therapy is recommended for patients with locally advanced breast cancer. Here the authors report the results of a phase 2 clinical trial of oral neoadjuvant therapy with pyrotinib (pan-HER tyrosine kinase inhibitor), letrozole (aromatase inhibitor) and dalpiciclib (CDK4/6 inhibitor) in patients with treatment-naïve and stage II-III triple positive breast cancer. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink